Pfizer’s Lyrica does not affect reproductive function in healthy males

Pfizer Inc. (NYSE: PFE) announced today that top-line results for Lyrica® (pregabalin) capsules CV Study A0081104 - Assessment of the Impact of Lyrica on Sperm Production in Healthy Volunteers - demonstrate that Lyrica does not affect the reproductive function in healthy males when compared to placebo. The study was conducted as a post-approval commitment required by the US Food and Drug Administration (FDA). Pfizer will continue to further analyze the study results.


Pfizer Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.